OrbiMed Advisors FATE Position
Exited10-Fund ConvergenceOrbiMed Advisors exited their position in Fate Therapeutics Inc. (FATE) in Q2 2025, after holding the stock for 7 quarters.
The position was first reported in Q4 2023 and has been tracked across 7 quarterly 13F filings.
FATE is a convergence signal: 10 specialist biotech funds hold this stock, suggesting high institutional conviction.
About Fate Therapeutics Inc.
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Full company profile →Short Interest
9.1%
5.4 days to cover
OrbiMed Advisors FATE Position History
Frequently Asked Questions
Does OrbiMed Advisors own FATE?
No. OrbiMed Advisors exited their position in Fate Therapeutics Inc. (FATE) in Q2 2025. They previously held the stock for 7 quarters.
How many hedge funds own FATE?
10 specialist biotech hedge funds currently hold FATE, including Redmile Group, Boxer Capital, Deep Track Capital and 7 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did OrbiMed Advisors first buy FATE?
OrbiMed Advisors's position in FATE was first reported in Q4 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is OrbiMed Advisors's FATE position increasing or decreasing?
OrbiMed Advisors completely exited their FATE position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
FATECompany Page →
All fund holders, insider trades, catalysts, and cash runway
OrbiMed AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →